Alterity Lands Rare Late-Breaker Slot to Present Disease-Modifying MSA Data

Alterity Therapeutics to present ATH434 disease-modifying data at major neurology conference

Alterity Therapeutics has secured a late-breaker oral presentation slot at the American Academy of Neurology (AAN) Annual Meeting, with Professor Daniel Claassen set to present data on the company’s lead Multiple System Atrophy (MSA) therapy ATH434 on 21 April 2026 in Chicago.

The presentation, titled “ATH434 Demonstrates Disease-Modifying Signal in Multiple System Atrophy Using the MuSyCA Composite Scale,” will take place during the Late-breaking Science 2 session on Tuesday 21 April 2026 at 6:21 PM CT. Professor Claassen, who serves as Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity, will deliver the findings at the conference running from 18-22 April 2026.

Late-breaker sessions at major medical conferences are competitively selected for data considered too significant to defer until the following year’s meeting. The selection of ATH434 data for oral presentation, rather than poster format, signals that the AAN scientific committee views the findings as meriting immediate dissemination to the neurology community. This peer recognition arrives as Alterity prepares to initiate its Phase 3 pivotal trial in MSA.

What is a late-breaker presentation and why does it matter?

Medical conferences reserve late-breaker sessions for research deemed scientifically important and time-sensitive. Acceptance into these competitive slots indicates that independent scientific review committees consider the data worthy of immediate attention, rather than waiting for standard abstract submission cycles that typically close six to eight months before a conference.

Oral presentations carry additional weight compared to poster displays. Conference organisers allocate limited oral slots to studies they believe will generate the most interest among attending physicians, researchers, and industry stakeholders. For biotechnology companies, late-breaker acceptance serves as external validation of clinical data quality and relevance.

Industry and institutional investors monitor major conference presentations for signals that regulatory submissions or commercialisation pathways may advance more rapidly than previously anticipated. The AAN Annual Meeting attracts neurologists, movement disorder specialists, and pharmaceutical industry representatives, making it a strategic venue for companies developing therapies for rare neurological conditions.

ATH434 and the Multiple System Atrophy opportunity

ATH434 is Alterity’s lead asset targeting MSA, a rare and rapidly progressive neurodegenerative disease with no approved disease-modifying treatments. The condition typically progresses faster than Parkinson’s disease, with patients experiencing severe motor and autonomic dysfunction.

The drug candidate has completed two Phase 2 clinical programmes:

• Randomised, double-blind, placebo-controlled Phase 2 trial showing clinically meaningful efficacy
• Open-label Phase 2 trial in participants with advanced MSA, also reporting positive data
• Phase 3 pivotal trial currently in preparation

The MuSyCA (Multiple System Atrophy Composite Assessment) scale referenced in the presentation title represents a composite measure designed to capture the multisystem nature of MSA progression. Use of composite endpoints can provide more comprehensive efficacy assessment than single-measure scales, potentially strengthening regulatory filing packages.

What’s next for Alterity Therapeutics?

Alterity is preparing to initiate its Phase 3 pivotal trial in MSA, with the AAN presentation timing positioned to generate scientific and investor visibility ahead of this catalyst. The presentation of Phase 2 data demonstrating disease-modifying signals using the MuSyCA scale may inform the design and endpoint selection for the upcoming Phase 3 programme.

Beyond ATH434, the company operates a drug discovery platform generating patentable compounds targeting underlying pathology in neurological diseases. This platform approach aims to create a pipeline beyond the lead MSA programme, though ATH434 remains the primary near-term value driver.

The company maintains a dual listing on the ASX (ATH) and NASDAQ (ATHE), with headquarters in Melbourne, Australia and San Francisco, USA. This dual-market structure provides access to both Australian biotechnology investors and US-based institutional funds that specialise in rare disease therapeutics.

Phase 3 initiation represents the next major milestone for Alterity. Conference presentations during the preparatory period maintain awareness among key opinion leaders and potential clinical trial investigators whilst the company finalises regulatory discussions and site selection for the pivotal study.

Want the Next Biotech Breakthrough in Your Inbox?

Join 20,000+ investors getting FREE breaking ASX news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive market-moving healthcare announcements the moment they hit the ASX, with expert coverage already done for you.